Companies/Abbott Laboratories

Company profile

Abbott Laboratories

NYSE: ABT · Healthcare · Medical - Devices

PublicHQ Abbott Park, ILCIK 0000001800Reports USD

#18 of 1,394 Healthcare companies by revenue50th-percentile growth

EA Score

87A

FH 88DQ 98GM 58SS 100

v0.1 · 65/100 weight · provisional

↑ market scale, workforce scale · ↓ 3-yr revenue growth, revenue growth (YoY)

Methodology →

Revenue TTM

$45.1B

Rev growth YoY (TTM)

+6.6%

Net income (FY)

$6.5B

Employees

114,000

Market cap

$166.2B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$44.3B$44.3B2025

Net income$6.5B$6.5B2025

Operating income$8.1B$8.1B2025

Total assets$86.7B$86.7B2025

Equity$52.1B$52.1B2025

Revenue trend

FY2019 – FY2025 · USD

$8.1B

FY19

$31.9B

FY19

$34.6B

FY20

$43.1B

FY21

$43.7B

FY22

$40.1B

FY23

$42.0B

FY24

$44.3B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Medical Devices48%

Diagnostic Products20%

Nutritional Products19%

Established Pharmaceutical Products12%

By geography

UNITED STATES40%

Non-US37%

D [E]6%

C [N]4%

C [H]4%

I [N]4%

The read

Abbott Laboratories booked $44.3B in FY2025 revenue, growing 5.7% year over year — about the middle of the pack among Healthcare companies we track, at a 14.7% net margin.

Peers · Healthcare

Gilead Sciences, Inc.87A Intuitive Surgical, Inc.90A Danaher Corporation87A Pfizer Inc.76B+

Key facts

CEORobert Ford

SectorHealthcare

IndustryMedical - Devices

HeadquartersAbbott Park, IL

ExchangeNYSE: ABT

Employees114,000

IPO date1980-03-17

Latest filings

10-Q2026-04-29 8-K2026-04-27 8-K2026-04-17 8-K2026-04-16 8-K2026-03-23 DEF 14A2026-03-13 8-K2026-03-09 8-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.